MaximBio of Maryland is ready to deliver 3 million COVID-19 rapid antigen tests by the end of 2020 and 15 million by Q2 2021. Their point-of-care test produces results in just 15 minutes.
Merck to Acquire Maryland-based OncoImmune’s Promising COVID-19 Drug in $425 Million Deal
Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The [….]
The Sixth Annual BioHealth Capital Region Forum brought together industry leaders from across the region who discussed the accomplishments and strengths of the region as its member companies continue to innovate new therapies and medicines in one of the strongest bio-hub regions in the United States.
Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.
